EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY 4.0

Safety and efficacy with esketamine in treatment-resistant depression: long-term extension study

Sicherheit und Wirksamkeit von Esketamin bei therapieresistenter Depression: Langzeit-Erweiterungsstudie

Naim Zaki iD, Li Nancy Chen, Rosanne Lane, Teodora Doherty, Wayne C Drevets, Randall L Morrison iD, Gerard Sanacora iD, Samuel T Wilkinson, Allan H Young, Acioly L T Lacerda, Jong-Woo Paik, Vanina Popova und 1 weitere

International Journal of Neuropsychopharmacology · 06.06.2025 · 28 (6)

DOI: 10.1093/ijnp/pyaf027 ↗

Auf einen Blick

In der offenen Langzeit-Erweiterungsstudie SUSTAIN-3 blieb die Verbesserung depressiver Symptome unter Esketamin plus oralem Antidepressivum bei vielen Teilnehmenden erhalten. Neue Sicherheitssignale wurden nicht identifiziert.

Fragestellung

Wie sicher und wirksam ist Esketamin-Nasenspray plus orales Antidepressivum langfristig bei TRD?

Methode

Phase-3, offene, einarmige Langzeit-Erweiterungsstudie (SUSTAIN-3) bei Erwachsenen mit TRD; Durchführung von Juni 2016 bis Dezember 2022 im ambulanten Setting.

Ergebnisse

1148 Patient:innen. Häufigste unerwünschte Ereignisse: Kopfschmerz 36,9 %, Schwindel 33,9 %, Übelkeit 33,6 %, Dissoziation 25,5 %. 5,3 % brachen wegen fehlender Wirksamkeit ab, 6,4 % wegen Nebenwirkungen.

Schlussfolgerung der Autor:innen

Im finalen Datensatz von SUSTAIN-3 wurden unter intermittierend dosiertem Esketamin keine neuen Sicherheitssignale gefunden; die Besserung der Depression hielt bei Teilnehmenden unter Erhaltungstherapie im Allgemeinen an.

Kernaussagen

  • Langzeitbehandlung mit Esketamin plus oralem Antidepressivum
  • Keine neuen Sicherheitssignale im finalen SUSTAIN-3-Datensatz
  • Depressive Symptome besserten sich und blieben unter Erhaltungstherapie verbessert

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift International Journal of Neuropsychopharmacology, online erschienen am 04.05.2025. Verfasst von Naim Zaki und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroscience, Johnson & Johnson, Titusville, NJ, United States. Hauptthemen laut MEDLINE: Ketamine, Depressive Disorder, Treatment-Resistant, Antidepressive Agents, Outcome Assessment, Health Care. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Janssen Research and Development, LLC.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance The rates of relapse and suicide risk are higher in treatment-resistant depression (TRD) vs non-treatment-resistant major depressive disorder. Even among patients with TRD who initially respond, the majority (70%) relapse within 6 months.

Objective

To evaluate the long-term safety and efficacy of esketamine nasal spray, combined with an oral antidepressant, in patients with TRD.

Design

Phase 3, open-label, single-arm long-term extension study (SUSTAIN-3) conducted from June 2016 to December 2022.

Setting

Outpatient.

Participants

Adults with TRD who participated in ≥1 of 6 phase 3 “parent” studies continued esketamine by either entering a 4-week induction phase followed by an optimization/maintenance phase of variable duration (n = 458) or directly entering the optimization/maintenance phase of SUSTAIN-3 (n = 690), based on their individual response to study drug at the endpoint of the parent study.

Interventions

Intranasal esketamine dosing was flexible, twice-weekly during induction and individualized to depression severity during optimization/maintenance (weekly, every-other-week, or every-4-weeks), under direct supervision by site staff. Main Outcomes and Measures To assess the long-term safety of esketamine. Efficacy endpoints included the change in depressive symptoms, assessed by the Montgomery-Åsberg Depression Rating Scale (MADRS).

Results

A total of 1148 patients were enrolled. Total exposure to esketamine was 3777 cumulative patient-years. Mean (median, range) exposure to esketamine in SUSTAIN-3 was 42.9 (45.8, range 0-79) months. The most common adverse events were headache (36.9%), dizziness (33.9%), nausea (33.6%), dissociation (25.5%), nasopharyngitis (23.8%), somnolence (23.1%), dysgeusia (20.2%), and back pain (20.0%). During the study, 5.3% and 6.4% of participants discontinued due to lack of efficacy or adverse event, respectively. Nine participants died: COVID-19-related (n = 3), pneumonia (n = 2), and completed suicide, myocardial infarction, multiple injuries, unknown cause (n = 1 each). The mean MADRS total score decreased during induction, and this reduction persisted during optimization/maintenance (mean [SD] change from baseline-to-phase endpoint of each phase: induction: −12.8 [9.73]; optimization/maintenance: + 0.2 [9.93]). A total of 35.6% of participants were in remission at the induction endpoint, and 48.5% and 49.6% at week 112 and optimization/maintenance endpoint, respectively. Conclusions and Relevance In the SUSTAIN-3 final dataset, no new safety signals were identified during long-term treatment with intermittently-dosed esketamine, combined with oral antidepressant, and improvement in depression generally persisted among participants who remained on maintenance treatment. These results add to the accumulated evidence on TRD treatment with esketamine. Trial Registration clinicaltrials.gov identifier: NCT02782104.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

KetamineDepressive Disorder, Treatment-ResistantAntidepressive AgentsOutcome Assessment, Health CareHumansMaleFemaleMiddle AgedAdultAdministration, IntranasalNasal SpraysAgedDrug Therapy, CombinationTreatment OutcomeCOVID-19

Stichwörter der Autor:innen

efficacyesketaminelong-termsafetytreatment-resistant depression

Substanzen

KetamineEsketamineAntidepressive AgentsNasal Sprays

Autor:innen und Institutionen

  • Department of Neuroscience, Johnson & Johnson, Titusville, NJ, United States.
  • Department of Clinical Biostatistics, Johnson & Johnson, Titusville, NJ, United States.
  • Department of Neuroscience, Johnson & Johnson, San Diego, CA, United States.
  • Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States.
  • Institute of Psychiatry, Psychology and Neuroscience, King's College, London, United Kingdom.
  • Department of Psychiatry, Federal University of Sao Paulo, Sao Paulo, Brazil.

ORCID-Profile: Naim Zaki, Randall L Morrison, Gerard Sanacora

Förderung

  • Janssen Research and Development, LLC

Zitieren

APA

Zaki, N., Chen, L. N., Lane, R., Doherty, T., Drevets, W. C., Morrison, R. L., Sanacora, G., Wilkinson, S. T., Young, A. H., Lacerda, A. L. T., Paik, J. W., Popova, V., & Fu, D. J. (2025). Safety and efficacy with esketamine in treatment-resistant depression: long-term extension study. International Journal of Neuropsychopharmacology, 28(6). https://doi.org/10.1093/ijnp/pyaf027

Vancouver

Zaki N, Chen LN, Lane R, Doherty T, Drevets WC, Morrison RL, et al. Safety and efficacy with esketamine in treatment-resistant depression: long-term extension study. International Journal of Neuropsychopharmacology. 2025;28(6). doi:10.1093/ijnp/pyaf027

BibTeX
@article{Zaki2025,
  author = {Zaki, Naim and Chen, Li Nancy and Lane, Rosanne and Doherty, Teodora and Drevets, Wayne C and Morrison, Randall L and Sanacora, Gerard and Wilkinson, Samuel T and Young, Allan H and Lacerda, Acioly L T and Paik, Jong-Woo and Popova, Vanina and Fu, Dong-Jing},
  title = {Safety and efficacy with esketamine in treatment-resistant depression: long-term extension study},
  journal = {International Journal of Neuropsychopharmacology},
  year = {2025},
  volume = {28},
  number = {6},
  doi = {10.1093/ijnp/pyaf027}
}
Kostenlos starten →